Clinical trials: Metformin
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes…
- Trial name
- NCT02420262
- Testing
- insulin degludec/liraglutide, insulin glargine, insulin aspart
- Where
- 117 sites in United States, Argentina and 10 more
- Volunteers
- 506 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period…
- Trial name
- GetGoal-Duo1 (NCT00975286)
- Testing
- Lixisenatide (AVE0010), Insulin glargine, Pen auto-injector
- Where
- 140 sites in United States, Argentina and 24 more
- Volunteers
- 446 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
The study compares 2 medicines for people with type 2 diabetes: insulin 287 (a new medicine) and insulin glargine (a medicine doctors can already prescribe).
- Trial name
- NCT03751657
- Testing
- Insulin icodec, Metformin, Dipeptidyl peptidase-4 inhibitors
- Where
- 49 sites in United States, Canada and 5 more
- Volunteers
- 247 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on…
- Trial name
- NCT00674466
- Testing
- 1.5 mg or 2.0 mg CJC-1134-PC
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- ConjuChem
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic…
- Trial name
- NCT01167881
- Testing
- BI 10773, Glimepiride
- Where
- 182 sites in United States, Argentina and 21 more
- Volunteers
- 1,549 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- AMPLITUDE-S (NCT03770728)
- Testing
- Efpeglenatide SAR439977, Background therapy: Metformin alone or in combination with SU
- Where
- 48 sites in United States, China and 1 more
- Volunteers
- 312 people
- Sponsor
- Sanofi
Healthy
5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA…
- Trial name
- NCT00835497
- Testing
- 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets, 5 mg/500 mg METAGLIP™ Tablets
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Type 2 Diabetes Mellitus
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks.
- Trial name
- NCT02526524
- Testing
- Met DR, Met IR
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 571 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Type 2 Diabetes Mellitus
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
The purpose of the study is to assess the effect of the addition of sitagliptin to metformin with or without a sulfonylurea compared with the addition of dapagliflozin to metformin with or without a sulfonylurea on hemoglobin A1c…
- Trial name
- NCT02532855
- Testing
- Sitagliptin, Dapagliflozin, Metformin
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin.
- Trial name
- NCT02036515
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Metformin
- Volunteers
- 464 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Sitagliptin and Glucagon Counterregulation
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
- Trial name
- SITACLAMP (NCT02256189)
- Testing
- Sitagliptin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26…
- Trial name
- DUAL™ II China (NCT03175120)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 37 sites in China, Hong Kong
- Volunteers
- 453 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)
The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes…
- Trial name
- NCT01181674
- Testing
- insulin glargine, metformin, acarbose
- Where
- Canada
- Volunteers
- 83 people
- Sponsor
- Population Health Research Institute
Diabetes Mellitus, Type 2, Diabetes
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus insulin detemir in combination with insulin aspart and metformin in subjects with very…
- Trial name
- SIMPLE (NCT01966978)
- Testing
- Metformin, Detemir, Liraglutide
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Texas Southwestern Medical Center
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo on Hemoglobin A1c (HbA1c) reduction at Week 26 in participant with type 2 diabetes (T2D) who have inadequate glycemic control…
- Trial name
- NCT03066830
- Testing
- Sotagliflozin (SAR439954), Metformin, Sulfonylurea
- Where
- 76 sites in United States, Bulgaria and 8 more
- Volunteers
- 507 people
- Sponsor
- Lexicon Pharmaceuticals
Sickle Cell Disease
Voxelotor CYP and Transporter Cocktail Interaction Study
This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are…
- Trial name
- NCT05981365
- Testing
- Voxelotor, Bupropion, Repaglinide
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
NAFLD
The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease
The goal of this study is to determine if NS-0200 can reduce the amount of liver fat in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This study will compare two doses of NS-0200 to placebo in NAFLD patients.
- Trial name
- NCT02546609
- Testing
- Leu-Met-Sil 0.5, Leu-Met-Sil 1.0
- Where
- 13 sites in United States
- Volunteers
- 91 people
- Sponsor
- NuSirt Biopharma
Obesity
Adipokines in Obese Adolescents With Insulin Resistance
The purpose of this study is to compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), High-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumour necrosis factor alpha (TNFα), before and after…
- Trial name
- NCT01410604
- Testing
- Metformin
- Where
- 2 sites in Mexico
- Volunteers
- 31 people
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
Diabetes Mellitus, Type 2
Foxiga Korea Local Phase 4 Study
To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month, randomised, open-label, parallel-group, multi-centre phase IV study.
- Trial name
- BEYOND (NCT02564926)
- Testing
- Dapagliflozin, Glimepiride
- Where
- 14 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Colorectal Neoplasms
Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
The purpose of this study is to investigate the effects of short term oral Metformin therapy on biomarkers for tumor growth in subjects with newly diagnosed colon or rectal adenocarcinoma.
- Trial name
- NCT01632020
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Arkansas